Please upgrade your browser.
Match the official cancer awareness color with its disease awareness month using this infographic.
We report final results with extended follow-up from a global, expanded-access trial that pre-regulatory approval provided sunitinib to metastatic renal cell carcinoma (mRCC) patients, ineligible for registration-directed trials.
Learn more about a type of kidney cancer called advanced renal cell carcinoma (aRCC) and the pathways involved in the disease in this animated whiteboard...
This exploratory study identified several biomarkers suggestive of adaptive immune activity that correlated with better clinical outcomes during nivolumab treatment.
Phase II results indicate promising efficacy of second-line treatment with lenvatinib alone or in combination with everolimus in mRCC.
Everolimus is a mTOR inhibitor that demonstrates antitumor and antiangiogenic activities.
Supported by funding from the ASCO Young Investigator Award from the Kidney Cancer Association. A research team led by Mayo Clinic oncologists has found a new way to...
Currently, there are no treatment options in the setting of recurrent or unresectable RCC IVC-TT. Even though RCC may be resistant to conventionally fractionated radiation therapy, hypofractionated radiation has shown excellent control rates for both primary and metastatic RCC.
A national independent market research organization is recruiting advanced and metastatic kidney cancer patients
Participants in this market research will be asked to provide feedback on their own experiences with advanced / metastatic kidney cancer and its treatment.
Activating genomic mutations in the mTOR pathway to predict responses to everolimus and temsirolimus
Supported, in part, by Kidney Cancer Association’s funding supporting this ASCO Merit Award. Samples from 79 of 94 patients were successfully sequenced and were included in the analysis.
|Powered by NeonCRM|